Investing.comCodex · 实盘不做把握 8/10
北京时间·🕒 发布 00:19:06时区推断·⟳ 抓取 00:20:33·⚡ 决策 07-23 08:02:06 +7h41m·96.5 天前
直觉外科股价创52周低点，二季度业绩虽超预期但美国手术量增速放缓
正文主要是52周低点和已披露财报/评级变化的复述，不是新的离散公司催化。
📄 原文Investing.com↗ 原文
Intuitive Surgical stock hits 52-week low at 342.06 USD
Wall Street makes small moves ahead of closely-watched tech earnings for AI cues Intuitive Surgical Inc’s stock reached…
不做 Intuitive Surgical（ISRG.US）
不做：这是52周低点和既有财报/评级信息的汇总，方向混杂且缺少新的可执行催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:扩散 high · price-in 风险 high ↗
关键理由
- 正文主要是52周低点和已披露财报/评级变化的复述，不是新的离散公司催化。
- 二季度EPS 2.80美元、收入28.9亿美元、美国da Vinci手术量约12%等信息属于业绩后背景，缺少相对当前时点的新超预期增量。
主要风险
- 若后续出现新的指引下修或核心手术量继续放缓，需作为新利空单独评估。
原文全文
展开原文 · 2,259 字
Wall Street makes small moves ahead of closely-watched tech earnings for AI cues
Intuitive Surgical Inc’s stock reached a 52-week low, hitting a price of $342.06. The stock currently trades at $341.92, near its 52-week low of $342.10, though InvestingPro analysis suggests the stock is undervalued at current levels, with a Fair Value indicating potential upside. This marks a significant point for the company, reflecting a challenging year with a 1-year change of -31.68%. The decline in stock price over the past year highlights the pressures and market conditions impacting Intuitive Surgical, a company known for its advanced robotic surgical systems. As the stock hits this new low, investors may be closely watching for any strategic moves or market shifts that could influence its future performance. The company maintains strong fundamentals with a market cap of $121.4 billion and robust revenue growth of ~21% over the last twelve months. For deeper insights, InvestingPro offers exclusive access to comprehensive Pro Research Reports and over a dozen additional ProTips for ISRG.
In other recent news, Intuitive Surgical reported second-quarter earnings that surpassed analyst expectations, with earnings per share reaching $2.80, exceeding estimates by 12%. The company’s revenue grew 19% to $2.89 billion, beating projections by 2.5%. Despite these positive results, Bernstein and Stifel both lowered their price targets for Intuitive Surgical, citing concerns about U.S. growth. Bernstein adjusted its price target from $750 to $685, while Stifel reduced it from $670 to $550, though both firms maintained positive ratings on the stock. BMO Capital, on the other hand, reiterated an Outperform rating with a $518 price target after the earnings beat. Intuitive Surgical’s U.S. da Vinci procedure growth slowed to approximately 12%, marking the slowest pace since 2021. The company’s full-year procedure growth guidance also fell short of investor expectations, contributing to a decrease in share value. Despite these concerns, the company achieved significant sales growth across its instruments, accessories, systems, and services.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Intuitive Surgical Inc’s stock reached a 52-week low, hitting a price of $342.06. The stock currently trades at $341.92, near its 52-week low of $342.10, though InvestingPro analysis suggests the stock is undervalued at current levels, with a Fair Value indicating potential upside. This marks a significant point for the company, reflecting a challenging year with a 1-year change of -31.68%. The decline in stock price over the past year highlights the pressures and market conditions impacting Intuitive Surgical, a company known for its advanced robotic surgical systems. As the stock hits this new low, investors may be closely watching for any strategic moves or market shifts that could influence its future performance. The company maintains strong fundamentals with a market cap of $121.4 billion and robust revenue growth of ~21% over the last twelve months. For deeper insights, InvestingPro offers exclusive access to comprehensive Pro Research Reports and over a dozen additional ProTips for ISRG.
In other recent news, Intuitive Surgical reported second-quarter earnings that surpassed analyst expectations, with earnings per share reaching $2.80, exceeding estimates by 12%. The company’s revenue grew 19% to $2.89 billion, beating projections by 2.5%. Despite these positive results, Bernstein and Stifel both lowered their price targets for Intuitive Surgical, citing concerns about U.S. growth. Bernstein adjusted its price target from $750 to $685, while Stifel reduced it from $670 to $550, though both firms maintained positive ratings on the stock. BMO Capital, on the other hand, reiterated an Outperform rating with a $518 price target after the earnings beat. Intuitive Surgical’s U.S. da Vinci procedure growth slowed to approximately 12%, marking the slowest pace since 2021. The company’s full-year procedure growth guidance also fell short of investor expectations, contributing to a decrease in share value. Despite these concerns, the company achieved significant sales growth across its instruments, accessories, systems, and services.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。